Answers are grounded in this paper and cite their sources.
Peptide inhibitor design targeting self‐assembly of amyloid‐ β (A β ) represents a promising strategy for suppressing the pathogenic mechanism of Alzheimer's disease (AD). Conventional approaches have primarily mimicked repetitive sequences found in fibrillar structures of A β aggregates. However, since the inherent flexibility of A β structures promotes the structural changes in the early‐stage oligomerization, a structural modulation should be considered in the design of peptide inhibitors. Herein, we introduce topological reprogramming of peptides to control the structural transformation in pathogenic A β 1–42 (A β 42). The eleven‐residue peptide scaffold P a11 ( 14 HQKLVNFAEDV 24 ) identified through the initial screening was dimerized via a disulfide bond. The dimerization stabilizes A β 42 into higher order structures by promoting antiparallel β ‐sheet conformations, thereby significantly suppressing A β 42 aggregation. Our approach underscores that modification in peptide connectivity would be a breakthrough for controlling the intrinsic flexibility of A β , surpassing the limitation in conventional, one‐dimensional peptide building block.
No takes yet. Share an insight, caveat, or question.
Im et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: